Search Results

There are 7038620 results for: content related to: Kidney Diseases

  1. Pharmacokinetic Interactions of Concomitant Administration of Febuxostat and NSAIDs

    The Journal of Clinical Pharmacology

    Volume 46, Issue 8, August 2006, Pages: 855–866, Reza Khosravan, Jing-Tao Wu, Nancy Joseph-Ridge and Laurent Vernillet

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006289848

  2. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia

    International Journal of Rheumatic Diseases

    Volume 18, Issue 6, July 2015, Pages: 669–678, Shaoyong Xu, Xiangyang Liu, Jie Ming, Shenren Chen, Yangang Wang, Xiumei Liu, Hong Liu, Yongde Peng, Jianqin Wang, Jinying Lin, Haiwang Ji, Bin Liu, Ying Lu, Peng Liu, Yonghong Zhang and Qiuhe Ji

    Version of Record online : 27 MAY 2015, DOI: 10.1111/1756-185X.12648

  3. Urate-Lowering Therapy for Gout: Focus on Febuxostat

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 30, Issue 6, June 2010, Pages: 594–608, Bryan L. Love, Robert Barrons, Angie Veverka and K. Matthew Snider

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.30.6.594

  4. Febuxostat for treating chronic gout

    Intervention Review

    The Cochrane Library

    Jean H Tayar, Maria Angeles Lopez-Olivo and Maria E Suarez-Almazor

    Published Online : 14 NOV 2012, DOI: 10.1002/14651858.CD008653.pub2

  5. Metabolism and Excretion of [14C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects

    The Journal of Clinical Pharmacology

    Volume 51, Issue 2, February 2011, Pages: 189–201, Mr Brian A. Grabowski, Dr Reza Khosravan, Dr Laurent Vernillet and Dr Darcy J. Mulford

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010365549

  6. The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase

    The Journal of Clinical Pharmacology

    Volume 46, Issue 1, January 2006, Pages: 88–102, Reza Khosravan, Brian A. Grabowski, Michael D. Mayer, Jing-Tao Wu, Nancy Joseph-Ridge and Laurent Vernillet

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270005282634

  7. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia

    International Journal of Rheumatic Diseases

    Volume 17, Issue 6, July 2014, Pages: 679–686, Xinfang Huang, Hui Du, Jieruo Gu, Dongbao Zhao, Lindi Jiang, Xinfu Li, Xiaoxia Zuo, Yi Liu, Zhanguo Li, Xiangpei Li, Ping Zhu, Juan Li, Zhiyi Zhang, Anbin Huang, Yuanchao Zhang and Chunde Bao

    Version of Record online : 28 JAN 2014, DOI: 10.1111/1756-185X.12266

  8. You have full text access to this OnlineOpen article
    Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial

    Arthritis & Rheumatology

    Volume 69, Issue 9, September 2017, Pages: 1903–1913, Nicola Dalbeth, Graeme Jones, Robert Terkeltaub, Dinesh Khanna, Jeff Kopicko, Nihar Bhakta, Scott Adler, Maple Fung, Chris Storgard, Scott Baumgartner and Fernando Perez-Ruiz

    Version of Record online : 4 AUG 2017, DOI: 10.1002/art.40159

  9. The Effect of Age and Gender on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase

    The Journal of Clinical Pharmacology

    Volume 48, Issue 9, September 2008, Pages: 1014–1024, Dr Reza Khosravan, Michael J. Kukulka, Jing-Tao Wu, Nancy Joseph-Ridge and Dr Laurent Vernillet

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008322035

  10. You have free access to this content
    The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate

    British Journal of Clinical Pharmacology

    Volume 74, Issue 2, August 2012, Pages: 327–335, Himanshu Naik, Jing-tao Wu, Robert Palmer and Lachy McLean

    Version of Record online : 10 JUL 2012, DOI: 10.1111/j.1365-2125.2012.04182.x

  11. Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study

    Hemodialysis International

    Volume 19, Issue 4, October 2015, Pages: 514–520, Yuki Tsuruta, Kan Kikuchi, Yukio Tsuruta, Yuko Sasaki, Takahito Moriyama, Mitsuyo Itabashi, Takashi Takei, Keiko Uchida, Takashi Akiba, Ken Tsuchiya and Kosaku Nitta

    Version of Record online : 21 MAY 2015, DOI: 10.1111/hdi.12313

  12. Emerging therapies in the long-term management of hyperuricaemia and gout

    Internal Medicine Journal

    Volume 37, Issue 4, April 2007, Pages: 258–266, L. K. Stamp, 1,2 J. L. O’Donnell and 2 P. T Chapman 1,2

    Version of Record online : 27 MAR 2007, DOI: 10.1111/j.1445-5994.2007.01315.x

  13. You have free access to this content
    2016 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 68, Issue S10, October 2016, Pages: 1–4550,

    Version of Record online : 8 NOV 2016, DOI: 10.1002/art.39977

  14. You have free access to this content
    Allopurinol for chronic gout

    Intervention Review

    The Cochrane Library

    Rakhi Seth, Alison SR Kydd, Rachelle Buchbinder, Claire Bombardier and Christopher J Edwards

    Published Online : 14 OCT 2014, DOI: 10.1002/14651858.CD006077.pub3

  15. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  16. You have free access to this content
    Women with gout: Efficacy and safety of urate-lowering with febuxostat and allopurinol

    Arthritis Care & Research

    Volume 64, Issue 2, February 2012, Pages: 256–261, Saima Chohan, Michael A. Becker, Patricia A. MacDonald, Solomon Chefo and Robert L. Jackson

    Version of Record online : 25 JAN 2012, DOI: 10.1002/acr.20680

  17. You have full text access to this OnlineOpen article
    Diabetes and gout: efficacy and safety of febuxostat and allopurinol

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 11, November 2013, Pages: 1049–1055, M. A. Becker, P. A. MacDonald, B. J. Hunt and R. L. Jackson

    Version of Record online : 12 JUN 2013, DOI: 10.1111/dom.12135

  18. You have full text access to this OnlineOpen article
    Effects of Febuxostat in Early Gout: A Randomized, Double-blind, Placebo-controlled Study

    Arthritis & Rheumatology

    Accepted manuscript online: 4 OCT 2017, Nicola Dalbeth, Kenneth G. Saag, William E. Palmer, Hyon K. Choi, Barbara Hunt, Patricia A. MacDonald, Ulrich Thienel and Lhanoo Gunawardhana

    DOI: 10.1002/art.40233

  19. You have free access to this content
    Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

    Arthritis & Rheumatism

    Volume 52, Issue 3, March 2005, Pages: 916–923, Michael A. Becker, H. Ralph Schumacher Jr., Robert L. Wortmann, Patricia A. MacDonald, William A. Palo, Denise Eustace, Laurent Vernillet and Nancy Joseph-Ridge

    Version of Record online : 4 MAR 2005, DOI: 10.1002/art.20935

  20. You have free access to this content
    Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 65, Issue 3, March 2008, Pages: 355–363, Reza Khosravan, Brian Grabowski, Jing-Tao Wu, Nancy Joseph-Ridge and Laurent Vernillet

    Version of Record online : 22 OCT 2007, DOI: 10.1111/j.1365-2125.2007.03016.x